Clinical trials
Hyperlipidemias trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
98 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 6 |
| 2020 | 7 |
| 2021 | 3 |
| 2022 | 8 |
| 2023 | 9 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 98 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 3 |
| Cairo University | 2 |
| China Medical University Hospital | 2 |
| Hanmi Pharmaceutical Company Limited | 2 |
| National Taiwan University Hospital | 2 |
| Olive Lifesciences Pvt Ltd | 2 |
| University Health Network, Toronto | 2 |
| University of Calgary | 2 |
| Alvogen Korea | 1 |
| Antalya Training and Research Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperlipidemias | 98 |
| Hypertension | 26 |
| Cardiovascular Diseases | 12 |
| Obesity | 12 |
| Diabetes Mellitus | 11 |
| Metabolic Syndrome | 9 |
| Hyperglycemia | 8 |
| Diabetes Mellitus, Type 2 | 7 |
| Atherosclerosis | 6 |
| Dyslipidemias | 6 |
Trials
Showing 51 to 75 of 98. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.